Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Indaptus is a clinical-stage biotechnology company developing Decoy20, a novel, systemically-administered anti-cancer and anti-viral immunotherapy. The technology utilizes attenuated, non-pathogenic Gram-negative bacteria to activate both innate and adaptive immune responses. The company is currently conducting a Phase 1 clinical trial for Decoy20 in patients with advanced solid tumors.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15.02) million | $(15.42) million |
| Operating Expenses | $(15.37) million | $(16.38) million |
| Cash and Cash Equivalents (Year End) | $5.79 million | $13.36 million |
| Cash Used in Operating Activities | $(12.32) million | $(13.41) million |
| Accumulated Deficit | $(60.44) million | $(45.42) million |
| Shares Outstanding (as of Mar 12, 2025) | 14,429,244 | N/A |
Note: The company has no revenue and is not profitable. Margins are not applicable.
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by approximately $0.4 million (2.6%) compared to 2023, primarily due to a reduction in total operating expenses.
- Operating Expenses: Total operating expenses decreased by $1.01 million (6.2%).
- Research & Development (R&D): Decreased by $0.37 million (4.9%) due to lower manufacturing process development costs, partially offset by increased Phase 1 clinical trial costs.
- General & Administrative (G&A): Decreased by $0.64 million (7.3%) driven by lower legal fees, recruitment costs, and insurance expenses.
- Liquidity: Cash and cash equivalents declined significantly from $13.36 million in 2023 to $5.79 million in 2024 due to operating cash burn.
- Financing Activity: The company raised approximately $4.8 million in net cash from financing activities in 2024 through registered direct offerings and ATM sales, compared to zero in 2023.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- Decoy20 Phase 1 Trial: As of March 12, 2025, more than 20 patients have been enrolled in weekly dosing cohorts. Early signs of potential benefits, including stable disease, have been observed.
- Combination Study: In October 2024, the company entered a supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab (anti-PD-1). The study is anticipated to begin in 2025.
- Expansion: In February 2025, the company received authorization from Health Canada to expand the U.S. clinical trial to Canadian sites.
Capital Resources and Going Concern
- Substantial Doubt: The company has identified conditions raising substantial doubt about its ability to continue as a going concern. It has incurred recurring losses and negative cash flows.
- Runway: Management believes cash on hand ($5.8 million) plus proceeds from a January 2025 financing ($2.0 million) will fund operations into the second quarter of 2025.
- Recent Financing:
- January 2025: Private placement raising ~$2.25 million gross.
- February 2025: Entered a Standby Equity Purchase Agreement (SEPA) with Yorkville allowing the sale of up to $20.0 million of common stock over 36 months.
Key Risks
- Capital Requirements: The company must raise additional capital to continue operations. Failure to do so may force delays or elimination of R&D programs.
- Nasdaq Compliance: On January 31, 2025, the company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has until July 30, 2025, to regain compliance or face delisting.
- Clinical Uncertainty: Clinical trials involve lengthy, expensive processes with uncertain outcomes. Adverse events or lack of efficacy could halt development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.8 million cash balance plus recent financing to fund operations through Q2 2025 and the timeline for the next capital raise.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by July 30, 2025, to avoid delisting.
- Clinical Data: Review upcoming data readouts from the Phase 1 trial, specifically regarding safety, dose-limiting toxicities, and the "stable disease" observations mentioned.
- Dilution Risk: Assess the potential dilution from the new $20 million SEPA facility and recent warrant issuances.
- Going Concern: Confirm the auditor's "going concern" qualification in the financial statements and management's specific plans to mitigate this risk.